A randomized trial of four cycles of adjuvant AC (adriamycin+ cyclophosphamide) ± two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer

Annals of Oncology

Volumn 12, Issue 7, 2001, Pages 1011-1013

  Icli F ^a   Akbulut, H ^a   Dincol D ^a   Onur, H ^a   Demirkazik, A ^a   Cam R ^a   Cay F ^a   Demirci, S ^a   Uner A ^a   Erekul, S ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Adjuvant chemotherapy; Adriamycin; Breast cancer; Cisplatin; Cyclophosphamide; Etoposide

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS;

EID: 0034904778     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011118004629     Document Type: Article

References (12)

1. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive node breast cancer patients tamoxifene-nonresponsive tumors results from the National Surgical Adjuvant Breast Bowel Project B15
2. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
3. Improved DFS and OS from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node positive primary breast cancer
4. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
5. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: A prospective randomized trial of the Italian Oncology Group for Clinical Research
6. Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer
7. Cisplatin and oral etoposide (PEO) in heavily pretreated patients with advanced breast cancer patients
8. Nonparametric estimation from incomplete observations
9. Polychemotherapy for early breast cancer: An overview of the randomized trials
10. Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF)
11. Severe vascular toxicity associated with cisplatin based chemotherapy